safinamide has been researched along with Neurodegenerative Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akkari, R; Borrmann, T; Brunschweiger, A; Drabczyńska, A; Hockemeyer, J; Kieć-Kononowicz, K; Koch, P; Köse, M; Küppers, P; Müller, CE; Radjainia, H; Schlenk, M | 1 |
| Baykov, S; Chirkova, Z; Engelbrecht, I; Korsakov, M; Osipyan, A; Petzer, A; Petzer, JP; Sapegin, A; Shetnev, A | 1 |
2 other study(ies) available for safinamide and Neurodegenerative Diseases
| Article | Year |
|---|---|
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; CHO Cells; Cricetulus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Purinergic P1 Receptor Antagonists; Purines; Xanthines | 2013 |
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
Topics: Dose-Response Relationship, Drug; Humans; Imidazoles; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Structure-Activity Relationship | 2019 |